NCT06376396Not yet recruitingPhase 4
Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis
Assessment of Combined Antiparasitic Drugs Praziquantel and Albendazole Versus Albendazole Alone in the Treatment of Active Parenchymal Neurocysticercosis in Tanzania and Zambia
Source: ClinicalTrials.gov · Last updated 23 Apr 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this clinical trial is to compare the combination albendazole and praziquantel versus albendazole alone in patients affected by neurocysticercosis.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 25 Feb 2024
- Start date
- 1 Jun 2024
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- R-Evolution Worldwide S.r.l. Impresa Sociale
- Diseases
- Epilepsy
- NCT number
- NCT06376396
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 300
- From 1 Jun 2024 to the primary completion date, 31 Dec 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Have uncontrolled hypertension and/or diabetes
- Have chronic consuming illness such as cancer or mental handicap to not allow them to follow the study instructions
- Have severe immunodeficiency eg. HIV/AIDS or Autoimmune diseases
- Already known allergies to albendazole or praziquantel
Other
- Women pregnant or breastfeeding
- Symptomatic NCC with cysts in extra-parenchymal location (sub-arachnoid and/or ventricles)
- Subject taking part in another clinical/pharmacological study in the 30 days preceding enrollment
Who the study is looking for
- Living in the study area for a continuous period of 3 years
- Adult aged 18 years and above
- Are willing and able to consent to this study
- Meet the definitions of active symptomatic NCC
- Have late onset of epilepsy or history of seizures, epileptic seizures
- Subjects willing to undergo diagnostic procedures
- Subjects medically stable enough for trial medication to be initiated
- Subjects willing to be hospitalized for 11-20 days to receive treatment for NCC
- Subjects willing to be followed up for one year following receipt of study medication
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.